Phase 3 Findings Highlight Hydromethylthionine Mesylate’s Potential as Alzheimer Treatment
When hydromethylthionine mesylate was compared with publicly available placebo decline data, the treatment effects of cognitive and functional decline are about 3-fold larger over 18 months.
Richard Stefanacci, DO, MGH, MBA
New 12-month findings from the phase 3 LUCIDITY study (NCT03446001) showed that hydromethylthionine mesylate (HMTM; TauRx Pharmaceuticals), an investigational tau aggregation inhibitor, demonstrated a positive effect on cognitive and functional decline in patients with disease severity ranging from mild cognitive impairment (MCI) to moderate Alzheimer disease (AD). Additionally, the therapy showed a safety profile that was consistent with previous trials, with no evidence of serious treatment-emergent adverse events or amyloid-related imaging abnormalities, known commonly as ARIA.1
On the coprimary cognitive and functional end points of change in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) and Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL23), treatment with a 16-mg/day dose resulted in minimal declines of 1.3 units and 1.0 units, respectively. TauRx noted that the expected decline over 12 months in an untreated population would be approximately 5.0 units on both scales.
Richard Stefanacci, DO, MGH, MBA, an assistant professor at Thomas Jefferson University, was named chief medical officer of TauRx to assist with the next stages of advancing the therapy. He said in statement that, "These data support our ability to pursue regulatory submissions. We look forward to making a significant difference addressing this global unmet need with a medication that is affordable, easy to administer, and safe."1
LUCIDITY is comprised of a 12-month double-blind, placebo-controlled phase followed by a 12-month, modified delayed-start, open-label treatment phase. The trial compared 16-mg doses of HMTM, a stable crystalline form of hydromethylthionine, the reduced form of methylthionine, with methylthioninium chloride (MTC) as an active placebo given at a dose of 4 mg twice weekly, the minimum required to prevent bias arising from potential urinary discoloration. MCT’s predecessor compound, Rember, was used in a phase 2 trial, and was found to be the only compoud to reliably discolor urine for this study blinding.
"This is the first time any treatment has produced evidence of sustained improvement over the individual's own pre-treatment baseline lasting 18 months at an early clinically detectable stage of AD, and stabilization of disease progression at more severe stages. The results in AD confirm published findings from two earlier HMTM Phase 3 trials," Claude Wishik, executive chairman and cofounder, TauRx, said in a statement.1 "This is the first time any treatment has produced evidence of sustained improvement over the individual's own pre-treatment baseline lasting 18 months at an early clinically detectable stage of AD, and stabilization of disease progression at more severe stages. The results in AD confirm published findings from two earlier HMTM Phase 3 trials."
In comparison, a majority of those on MTC 4 mg twice weekly had blood levels of the ative drug above the threshold needed to produce a clinical effect. Because the arm was technically not a therapeutically inactive placebo, outcomes could not have been fully compared. In light of the data, the company noted that it does not believe a valid blinded placebo-controlled trial of HMTM with clinical end points is technically feasible; however, the relationship between blood concentration of drug and treatment effect, change from pretreatment baseline, and comparisons against historical controls from the Alzheimer’s Neuroimaging Initiative (ADNI), were still conducted.
The MCI group (n = 105), which had baseline Mini Mental State Examination (MMSE) scores of 23, showed statistically significant improvements of 2 units over the pretreatment baseline at 6 months (P = .0002), 12 months (P = .0391), and 18 months (P = .0473) on ADAS-Cog13 scale after treatment with 16-mg/day dose. Similarly, those with mild to moderate AD (n = 147) demonstrated a 2.5-unit cognitive decline on ADAS-Cog13 in the first 9 months and no further decline over the following 9 months.
On ADCS-ADL, the mean change remained above the pretreatment baseline at 6, 12, and 18 months for those with MCI, while functional decline was represented by a change of –2 units at 12 months and –3 units at 18 months for those with mild-to-moderate AD. The findings from the mild-to-moderate group represented a reduction in decline of about 75% relative to a published meta-analysis of publicly available placebo decline data from historical trials.
Additional findings from LUCIDITY showed statistically significant reductions in disease progression as measured by change in cognitive function (P = .0008) and brain atrophy (P <.0001) that were confirmed by comparisons of participants receiving the 16-mg/day dose against participants from ADNI who were closest to the study population by age and clinical severity. These findings were consistent regardless of whether patients had MCI or mild to moderate AD. Those treated with HMTM 16 mg/day had a rate of progression of brain atrophy that was significantly less than in ADNI patients with MCI (P <.0001) and comparable to that seen in ADNI healthy aging subjects.
Wischik added, "Tau pathology of the disease is now recognized as an important target for treatment, and it is encouraging that cognitive improvement is seen at such an early stage of the disease with a drug targeting Tau. The field has focused mainly on amyloid as a target for early intervention. Our data are consistent with the evidence that Tau pathology begins at least 20 years before clinical symptoms appear and is a viable first-line target for treatment."1
In a previous phase 3 study of HMTM, investigators found changes in ADAS-Cog, ADCS-ADL, MRI atrophy, and glucose uptake that were above the required threshold of P <.025 to be considered statistically significant. In that study, 800 patients with mild AD were assigned to 100 mg twice a day or 4 mg twice per day. Prior to unblinding, the Statistical Analysis Plan was revised to compare the 100 mg twice per day as a monotherapy subgroup (n = 79) vs 4 mg twice per day as randomized (n = 396), and 4 mg twice per day as monotherapy (n = 76) vs 4 mg twice per day as add-on therapy. After brain atrophy rate initially showed similar rates to mild AD in both add-on and monotherapy groups, the rate continued to decline 9 months after treatment in those on monotherapy compared with elderly controls.2
